CN111920799A - 一种苦乐果有效成分组合物及其制备方法和应用 - Google Patents
一种苦乐果有效成分组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN111920799A CN111920799A CN202010816803.XA CN202010816803A CN111920799A CN 111920799 A CN111920799 A CN 111920799A CN 202010816803 A CN202010816803 A CN 202010816803A CN 111920799 A CN111920799 A CN 111920799A
- Authority
- CN
- China
- Prior art keywords
- component
- fraction
- composition
- eluting
- drying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 65
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 210000004369 blood Anatomy 0.000 claims abstract description 69
- 239000008280 blood Substances 0.000 claims abstract description 69
- QOFWRHWADNWKSU-LRXIOGKNSA-N (2e,6e,10e)-13-[(2r)-6-hydroxy-2,8-dimethyl-3,4-dihydrochromen-2-yl]-2,6,10-trimethyltrideca-2,6,10-trienoic acid Chemical compound OC1=CC(C)=C2O[C@@](CC/C=C(C)/CC\C=C(CC\C=C(/C)C(O)=O)/C)(C)CCC2=C1 QOFWRHWADNWKSU-LRXIOGKNSA-N 0.000 claims abstract description 34
- 230000001603 reducing effect Effects 0.000 claims abstract description 30
- 238000001035 drying Methods 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 26
- 230000000694 effects Effects 0.000 claims abstract description 23
- QOFWRHWADNWKSU-UHFFFAOYSA-N (11'E)-delta-Tocotrienol acid Natural products OC1=CC(C)=C2OC(CCC=C(C)CCC=C(CCC=C(C)C(O)=O)C)(C)CCC2=C1 QOFWRHWADNWKSU-UHFFFAOYSA-N 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 20
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 18
- 239000003814 drug Substances 0.000 claims abstract description 16
- 239000007791 liquid phase Substances 0.000 claims abstract description 10
- 230000008569 process Effects 0.000 claims abstract description 10
- 238000000605 extraction Methods 0.000 claims abstract description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 84
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 56
- 239000000843 powder Substances 0.000 claims description 43
- 239000000284 extract Substances 0.000 claims description 36
- HQVFCQRVQFYGRJ-UHFFFAOYSA-N formic acid;hydrate Chemical compound O.OC=O HQVFCQRVQFYGRJ-UHFFFAOYSA-N 0.000 claims description 24
- 238000010828 elution Methods 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 19
- 238000002137 ultrasound extraction Methods 0.000 claims description 13
- 238000001914 filtration Methods 0.000 claims description 11
- 239000012071 phase Substances 0.000 claims description 9
- 230000002441 reversible effect Effects 0.000 claims description 9
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 abstract description 21
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 14
- 201000001421 hyperglycemia Diseases 0.000 abstract description 12
- 230000002195 synergetic effect Effects 0.000 abstract description 10
- 235000010205 Cola acuminata Nutrition 0.000 abstract description 3
- 244000228088 Cola acuminata Species 0.000 abstract description 3
- 239000002994 raw material Substances 0.000 abstract description 2
- 241000173529 Aconitum napellus Species 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 description 16
- 241000700159 Rattus Species 0.000 description 12
- 210000002196 fr. b Anatomy 0.000 description 12
- 210000003918 fraction a Anatomy 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 241001207073 Garcinia kola Species 0.000 description 7
- 238000007873 sieving Methods 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 230000002218 hypoglycaemic effect Effects 0.000 description 6
- 238000010298 pulverizing process Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 5
- 201000005577 familial hyperlipidemia Diseases 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 108010028554 LDL Cholesterol Proteins 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 239000012620 biological material Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000000055 hyoplipidemic effect Effects 0.000 description 4
- GJWXCPDVDRIBKP-CNTBMXMRSA-N kolaflavanone Chemical group C1=C(O)C(OC)=CC=C1[C@@H]1[C@@H](O)C(=O)C2=C(O)C=C(O)C([C@H]3C(C4=C(O)C=C(O)C=C4O[C@@H]3C=3C=CC(O)=CC=3)=O)=C2O1 GJWXCPDVDRIBKP-CNTBMXMRSA-N 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 230000001360 synchronised effect Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 102000004506 Blood Proteins Human genes 0.000 description 3
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- -1 nicotinic acid lipid Chemical class 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 3
- MXEIKUWMKSYEII-UHFFFAOYSA-N (+)-GB-1b Natural products C1=CC(O)=CC=C1C1OC2=C(C3C(C4=C(O)C=C(O)C=C4OC3C=3C=CC(O)=CC=3)=O)C(O)=CC(O)=C2C(=O)C1 MXEIKUWMKSYEII-UHFFFAOYSA-N 0.000 description 2
- MXEIKUWMKSYEII-DETITRACSA-N (2s)-8-[(2s,3r)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-2,3-dihydrochromen-3-yl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=C([C@H]3C(C4=C(O)C=C(O)C=C4O[C@@H]3C=3C=CC(O)=CC=3)=O)C(O)=CC(O)=C2C(=O)C1 MXEIKUWMKSYEII-DETITRACSA-N 0.000 description 2
- UFJORDZSBNSRQT-UHFFFAOYSA-N 3-(4-oxo-2-phenylchromen-3-yl)-2-phenylchromen-4-one Chemical class O1C2=CC=CC=C2C(=O)C(C=2C(C3=CC=CC=C3OC=2C=2C=CC=CC=2)=O)=C1C1=CC=CC=C1 UFJORDZSBNSRQT-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000000260 hypercholesteremic effect Effects 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 235000015438 Cola nitida Nutrition 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 239000005947 Dimethoate Substances 0.000 description 1
- 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 description 1
- 241000593508 Garcinia Species 0.000 description 1
- 235000000885 Garcinia xanthochymus Nutrition 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 235000002710 Ilex cornuta Nutrition 0.000 description 1
- 241001310146 Ilex cornuta Species 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 240000003450 Mallotus philippensis Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000010326 Osmanthus heterophyllus Nutrition 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940097217 cardiac glycoside Drugs 0.000 description 1
- 239000002368 cardiac glycoside Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 229940125753 fibrate Drugs 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Natural products OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 229930002534 steroid glycoside Natural products 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (11)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010816803.XA CN111920799B (zh) | 2020-08-14 | 2020-08-14 | 一种苦乐果有效成分组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010816803.XA CN111920799B (zh) | 2020-08-14 | 2020-08-14 | 一种苦乐果有效成分组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111920799A true CN111920799A (zh) | 2020-11-13 |
CN111920799B CN111920799B (zh) | 2023-05-12 |
Family
ID=73310349
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010816803.XA Active CN111920799B (zh) | 2020-08-14 | 2020-08-14 | 一种苦乐果有效成分组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111920799B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114306413A (zh) * | 2022-01-14 | 2022-04-12 | 苏州隽德生物科技有限公司 | 一种苦乐果湿疹膏的制备方法及设备 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140142171A1 (en) * | 2012-11-21 | 2014-05-22 | Laboratoire Shigeta | Anti-glycation agent comprising a garcinia kola extract or fraction |
KR20180128781A (ko) * | 2017-05-24 | 2018-12-04 | 주식회사 씨티씨바이오 | 콜라비론의 제조방법 |
-
2020
- 2020-08-14 CN CN202010816803.XA patent/CN111920799B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140142171A1 (en) * | 2012-11-21 | 2014-05-22 | Laboratoire Shigeta | Anti-glycation agent comprising a garcinia kola extract or fraction |
KR20180128781A (ko) * | 2017-05-24 | 2018-12-04 | 주식회사 씨티씨바이오 | 콜라비론의 제조방법 |
Non-Patent Citations (4)
Title |
---|
IBANGA I. ETIM等: "Hypoglycemic and Hypolipidemic Effect of Bitter Kola (Garcinia kola) Seed Extract on Alloxan-Induced Diabetic Albino Rats", 《JOURNAL OF BIOSCIENCES AND MEDICINES》 * |
ISAAC A. ADEDARA等: "Garcinia kola seed ameliorates renal, hepatic, and testicular oxidative damage in streptozotocin-induced diabetic rats", 《PHARM BIOL》 * |
M.K. TCHIMENE等: "Anti-diabetic Profile of Extract, Kolaviron, Biflavonoids and Garcinoic acid from Garcinia kola seeds", 《INT.J.CURR.MICROBIOL.APP.SCI》 * |
XINHUI WANG等: "Study on characteristics of biflavanones distribution in Garcinia kola seeds and identification of compounds in gum resin exuded fromfresh slices", 《JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114306413A (zh) * | 2022-01-14 | 2022-04-12 | 苏州隽德生物科技有限公司 | 一种苦乐果湿疹膏的制备方法及设备 |
Also Published As
Publication number | Publication date |
---|---|
CN111920799B (zh) | 2023-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7811997B2 (en) | Composition containing total triterpenoid sapogenins extracted from bamboo, and the preparation method and use thereof | |
CN1669573A (zh) | 一种治疗心脑血管疾病的中药制剂及其制备方法 | |
CN111704639B (zh) | 核桃分心木中酚酸葡萄糖苷类化合物的分离方法及应用 | |
CN107837301B (zh) | 一种大叶蒟提取物及其制备方法与应用 | |
WO2008145064A1 (fr) | Procédé d'obtention d'un extrait contenant du séquoyitol à partir d'une espèce du genre trifolium, de soja et de ginkgo biloba, et utilisation de celui-ci | |
CN112791137B (zh) | 三种五味子提取物及其制备工艺和应用 | |
CN111920799B (zh) | 一种苦乐果有效成分组合物及其制备方法和应用 | |
CN109954024B (zh) | 一种蒲桃果实有效部位及其制备方法和在制备具有降血糖作用的药物或食品中的应用 | |
CN106822331A (zh) | 以锁状多聚体多酚为主的荔枝皮提取物在制备治疗高尿酸血症药物或保健品中的应用 | |
KR100979459B1 (ko) | 근육세포에서 포도당 흡수를 증가시키는 데이츄 추출물과이로부터 분리한 4h-크로멘-4-온 유도체 | |
CN102579530A (zh) | 具有抗糖尿病作用的太白楤木总皂苷的制备方法及药物 | |
KR20130074121A (ko) | 초음파 처리를 이용한 인삼 프로사포게닌 고농도 함유 삼칠삼 제제 및 이의 제조방법 | |
CN113925948B (zh) | 生姜总提取物或其活性成分的用途、药物组合物和制法 | |
JP2021512997A (ja) | 分離された防風多糖及びその用途 | |
CN106822071B (zh) | 一种用于治疗冠心病、高脂血症的中药有效部位、制备方法及从中分离有效成分的方法 | |
CN110143989B (zh) | 一种鞣花单宁类α-葡萄糖苷酶抑制剂及其制备方法 | |
CN107513092B (zh) | 一种丙二酰基人参皂苷Rb1的制备方法及其医用用途 | |
CN116509921B (zh) | 米团花二倍半萜提取物k01在制备治疗脓毒血症的药物中的应用 | |
WO2023125719A1 (zh) | 一种水苦荬提取物及其制备方法和应用 | |
CN111388457B (zh) | 3`-香叶基柑橘查尔酮及组合物在制备治疗脂肪肝的产品方面中的应用 | |
CN110050933B (zh) | 一种含蒲桃果实有效部位的降血糖固体饮料及其制备方法 | |
US20220133835A1 (en) | Antidiabetic composition comprising ginger extract obtained from microwave-processed ginger and method of preventing or treating diabetis mellitus | |
KR20170108432A (ko) | 치커리 추출물을 함유한 당뇨병 치료용 약학조성물 | |
CN116350681A (zh) | 一种水苦荬提取物及其制备方法和应用 | |
CN114767695A (zh) | 水葱内酯的提取方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240613 Address after: Unit E667, 5th Floor, Lecheng Plaza, Phase II, No. 218 Sangtian Street, Suzhou Industrial Park, Suzhou Area, Suzhou Free Trade Zone, Jiangsu Province, 215000 Patentee after: Suzhou Junde Biotechnology Co.,Ltd. Country or region after: China Address before: No. 1, Unit 1, 47th Floor, Jun'an Jingyuan, South Side of Qingnan Road, High tech Zone, Tangshan City, Hebei Province, 063000 Patentee before: Tangshan kelifuti Biotechnology Co.,Ltd. Country or region before: China |